The INCA Trial: A Multicenter, Randomized, Phase II, Open-Label Clinical Trial to Evaluate the Combination Therapy With Ipilimumab Plus Nivolumab Versus Chemotherapy (Pemetrexate-Cisplatin) in Patients With Advanced Non-Squamous NSCLC Naive to Treatment. PPCR 2018, 4 (1), 6-13.